拜瑪林製藥 BMRN 深 滬
已收盤 09-19 16:00:00 美东时间
71.41
+0.270
+0.38%
華盛通- 最 高72.07
- 今 開71.75
- 成交量 293.45万股
- 最 低 70.42
- 昨 收 71.14
- 總市值 134.96亿
- 52周最高 99.56
- 市盈率 靜 81.61
- 換手率 1.55%
- 52周最低 68.8309
- 委 比 -40.05%
- 總股本 1.89亿
- 歷史最高 151.75
- 量 比 0.73
- 振 幅 2.32%
- 歷史最低 23.735
- 每 手 1
- 風險率 5.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-17 21:01
BioMarin off 17% as Ascendis data seen as threat to Voxzogo
BioMarin Pharmaceutical (NASDAQ:BMRN) is down ~17% Monday following positive data from an Ascendis Pharma (ASND) achondroplasia candidate that could challenge the former's Voxzogo. Data from the pivot...
09-17 02:59
Goldman's ‘Goldilocks’ mid-cap picks that trade at reasonable valuations
Goldman Sachs analysts listed 25 mid-cap stocks that have quality and growth attributes and that trade at attractive valuations relative to their history. Each of these companies trade at a next-12-mo...
09-11 23:32
Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Cigna (CI)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-09 18:41
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enhance growth.
09-05 21:51
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
Ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) were provided by 14 analysts ...
09-05 21:00
Truist Securities Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $118
Truist Securities analyst Robyn Karnauskas maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $140 to $118.
09-05 20:12
Barclays Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Barclays analyst Gena Wang maintained a Buy rating on BioMarin Pharmaceutical (...
09-05 17:16
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow breakeven target. Analysts remain optimistic about Yorvipath's market potential despite challenges.
09-05 05:02
BioMarin plans $500M cost transformation to improve margins
BioMarin Pharmaceutical (NASDAQ:BMRN) introduced its longer-term outlook and plans to implement a $500M cost transformation program at its investor day event today. The New York-based pharma has under...
09-05 02:07
